Investor Relations

Press Releases

Advaxis to Present at International Anal Neoplasia Society Scientific Meeting 2015

Read More

Advaxis Completes $23 Million Financing

Read More

Advaxis Appoints Mayo Pujols Vice President, Manufacturing

Read More

Advaxis Forms Clinical Trial Collaboration With Incyte to Evaluate Investigational Combination of Two Novel Cancer Immunotherapies for Early Stage Cervical Cancer

Read More

Gynecologic Oncology Group (GOG) Phase 2 Study of Advaxis's Lm-LLO Immunotherapy, ADXS-HPV, for the Treatment of Persistent or Recurrent Cervical Cancer Achieves Safety and Efficacy Criteria

Read More

Advaxis Announces FDA Acceptance of Its Investigational New Drug Application to Commence First-in-Human Clinical Trials of ADXS-HER2

Read More

Advaxis to Host Analyst & Investor Day on February 3, 2015

Read More

Advaxis to Present at the Noble Financial Capital Markets 11th Annual Investor Conference

Read More

Advaxis Provides 2014 Year-End Review and 2015 Outlook

Read More

Advaxis and the GOG Foundation, Inc. to Collaborate on Global Phase 3 Clinical Trial of ADXS-HPV in Cervical Cancer

Read More